all report title image
  • Published On : Mar 2022
  • Code : CMI4958
  • Industry : Pharmaceutical
  • Pages : 167
  • Formats :

Lupus is a chronic autoimmune disease wherein the body’s immune system fails to recognize its cells and tissues as self and starts attacking them. The four major types of lupus include systemic lupus erythematosus (SLE), cutaneous lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus. Systemic lupus erythematosus is the most common type of lupus that causes damage to several organs throughout the body such as the kidney, lungs, heart, and others. Systemic lupus erythematosus causes inflammation in the skin, joints, lungs, blood cells, kidneys, etc. This condition usually goes through cycles of flare-ups (symptoms appear) and remissions (symptoms disappear). In discoid lupus erythematosus (a type of cutaneous lupus erythematosus), the symptoms affect only the skin, thus causing circular lesions on areas such as scalp, face, etc. These lesions may become thick and scaly and in some cases, lead to scarring and skin discoloration. Drug-induced lupus erythematosus may be caused due to medication such as hydralazine, procainamide, isoniazid, etc. The symptoms of drug-induced lupus erythematosus are similar to SLE but are often less severe. Neonatal lupus is an autoimmune condition that occurs when a mother passes on an antibody (anti-Ro/SSA antibody, anti-La/SSB antibody, etc.) to the infant through placenta. These antibodies may cause symptoms such as skin rash, low blood counts, congenital heart defect, and others at birth.

The global lupus therapeutic market is estimated to be valued at US$ 2,795.2 million in 2022 and is expected to exhibit a CAGR of 8.6% over the forecast period (2022-2030).

Figure 1. Global Lupus Therapeutic Market Share (%), By Region, 2022

Lupus Therapeutic  | Coherent Market Insights

The increasing research and development activities for the development of novel therapeutics for the treatment of lupus is expected to drive the market growth over the forecast period.

For instance, in November 2021, AstraZeneca, a U.K. based biopharmaceutical company announced positive results from its TULIP Phase 3 clinical trial program (focused on determining the efficacy and safety of Anifrolumab), stating that Saphnelo (anifrolumab) - a human monoclonal antibody showed greater reduction of SLE when used in combination with standard therapy than the use of only standard therapy.

CMI table icon

Lupus Therapeutic Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 2,795.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 8.6% 2030 Value Projection: US$ 5,408.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Disease Type: Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, Neonatal Lupus,
  • By Treatment Type: Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Biologics, Antimalarial Drugs, Corticosteroids, Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
  • By Route of Administration: Oral, Subcutaneous, Intravenous, Others (Intramuscular, Intradermal, among others)
  • By End User: Hospitals & Clinics, Diagnostic Laboratories, Others (Homecare, Specialty Centre, among others)
Companies covered:

Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh

Growth Drivers:
  • Increasing prevalence of lupus
  • Increasing products approval and launches by market players
Restraints & Challenges:
  • Adverse events/side effects associated with drugs used for treatment of lupus

Figure 2. Global Lupus Therapeutic Market Value (US$ Mn), By Disease Type, 2022

Lupus Therapeutic  | Coherent Market Insights

Key players operating in the market are focusing on submitting applications for the approval of novel drugs to be used in the treatment of lupus, which is expected to drive growth of the global lupus therapeutic market over the forecast period.

For instance, in December 2020, GlaxoSmithKline plc, a U.K. based pharmaceutical company announced that it has received the U.S. Food and Drug Administration (FDA) approval for its drug BENLYSTA (belimumab) to be used in combination with standard therapy for treatment of adult patients with active lupus nephritis (LN), a kidney disease caused due to SLE.

Global Lupus Therapeutic Market – Impact of Coronavirus (Covid-19) Pandemic

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was first reported from Wuhan, China in December 2019, and was declared as a global pandemic by the World Health Organization (WHO), which designates this SARS-CoV-2 infection as novel Coronavirus (COVID-19). According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread across the globe infecting over 409 million population leading to more than 5.8 million deaths as of February 13, 2022. The negative impact of COVID-19 on the healthcare domain is huge and it has significantly disrupted the healthcare industries’ entire supply chain, from raw materials to manufacturing and delivery. Similarly, the COVID-19 pandemic is expected to show a positive impact on the overall growth of the lupus therapeutics market owing to the association of COVID-19 with lupus.

For instance, according to an article published by the Journal of Medical Case Reports in January 2021, association between COVID-19 and lupus is not yet determined but it suggests that COVID-19 could be a potential agent which is responsible for producing autoantibodies and causing systemic lupus erythematosus. The same source also discusses a case report of a 39 year old male in Iran who has been the first case of SLE manifestation following COVID-19.

Global Lupus Therapeutic Market - Restraint

The side effects of drugs used for treatment of lupus is one of the major factors that are expected to hinder growth of the global lupus therapeutic market over the forecast period. For instance, according to an article published by the Lupus Science and Medicine journal (a peer-reviewed, open access journal) in March 2018, nearly all patients undergoing treatment for SLE report one or more adverse events such as nausea, vomiting, bone toxicity, and others.

Key Players

Major players operating in the global lupus therapeutic market include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.

Lupus is an autoimmune disorder wherein the immune system of the body attacks body’s own healthy tissues and organs, resulting in swelling, tissue damage, and pain. The inflammation caused by lupus can affect the joints, kidneys, brain, blood cells, skin, heart, and lungs. The exact cause of lupus is unknown, however, certain risk factors are associated with lupus. These risk factors include hormones, genetics, smoking, viral infection, and others. Some of the common symptoms related to lupus include fatigue, muscle and joint pain, fever, mouth ulcers, headaches, arthritis, malar rash, unusual hair loss, and others. Diagnosis of lupus is difficult as its symptoms mimic those of other ailments such as rheumatoid arthritis, scleroderma, etc. However, a butterfly-shaped rash, also known as malar rash across the nose and cheek is a highly distinctive feature of lupus. There are other complications that can arise from lupus, such as urinary tract infections, yeast infections, herpes, pregnancy loss, bone tissue death, and others.        

Market Dynamics

The high prevalence and incidence of lupus, rapid research and development activities towards development of novel therapeutics for treatment of lupus, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global lupus therapeutic market over the forecast period.

For instance, according to an article published by the Lupus Science and Medicine journal, in April 2021, it is estimated that the incidence and prevalence of Systemic Lupus Erythematosus (SLE) were around 0.3 to 5.1 per 100 000 per year and 6.5 to 85 per 100 000 population, respectively in Europe in 2020.

Key features of the study:

  • This report provides an in-depth analysis of the global lupus therapeutic market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global lupus therapeutic market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global lupus therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lupus therapeutic market

Detailed Segmentation:

  • Global Lupus Therapeutic Market, By Disease Type:
    • Systemic Lupus Erythematosus (SLE)
    • Cutaneous Lupus Erythematosus
    • Drug-Induced Lupus Erythematosus
    • Neonatal Lupus
  • Global Lupus Therapeutic Market, By Treatment Type:
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • Biologics
    • Antimalarial Drugs
    • Corticosteroids
    • Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
  • Global Lupus Therapeutic Market, By Route Of Administration:
    • Oral
    • Subcutaneous
    • Intravenous
    • Others (Intramuscular, Intradermal, among others)
  • Global Lupus Therapeutic Market, By End User:
    • Hospitals & Clinics
    • Diagnostic Laboratories
    • Others (Homecare, Specialty Centre, among others)
  • Global Lupus Therapeutic Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Hikma Pharmaceuticals PLC*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Lupus Therapeutics
    • Dr. Reddy's Laboratories Ltd.
    • GlaxoSmithKline plc
    • Amgen Inc.
    • Novartis AG
    • Sanofi
    • UCB S.A.
    • ImmuPharma PLC
    • Bayer AG
    • Merck & Co., Inc.
    • Aurinia Pharmaceuticals Inc.
    • Pfizer Inc.
    • ADMA Biologics, Inc.
    • AstraZeneca
    • F.Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Boehringer Ingelheim International Gmbh

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global lupus therapeutic market size is estimated to be valued at US$ 2,795.2 million in 2022 and is expected to exhibit a CAGR of 8.6% between 2022 and 2030.
Increasing prevalence of lupus and increasing research and development activities for the development of novel therapeutics to be used for the treatment of lupus are expected to drive the market growth over the forecast period.
Systemic Lupus Erythematosus (SLE) segment is expected to hold a major market share in the market.
North America holds the largest market share in the market.  
Major factors hampering growth of the market include adverse events/side effects associated with drugs used for the treatment of lupus.
Major players operating in the market include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo